EXENATIDE PACKAGE INSERT PDF
BYETTA is a non-insulin type 2 diabetes injection medication for adults. Important Safety Information for BYETTA (exenatide) injection . with prior severe hypersensitivity reactions to exenatide or to any of the product components. Byetta 5 micrograms solution for injection in pre-filled pen. Byetta 10 micrograms solution for injection in pre-filled pen exenatide. Read all of this leaflet carefully.
|Published (Last):||2 April 2018|
|PDF File Size:||10.15 Mb|
|ePub File Size:||5.50 Mb|
|Price:||Free* [*Free Regsitration Required]|
When used with insulin, evaluate and consider reducing the insulin dose packxge patients at increased risk of hypoglycemia. Increased risk of hypoglycemia when used in combination with a sulfonylurea SU or when used with a glucose-independent insulin secretagogues eg, meglitinides.
Because exenatide exenatdie commonly associated with gastrointestinal adverse reactions, BYETTA is not recommended in patients with severe gastrointestinal disease eg gastroparesis. This site is intended for US Consumers. Go to Healthcare Professional Site. Tell your healthcare provider if you have or had kidney problems or a kidney transplant.
Type 2 Diabetes Medication | BYETTA® (exenatide) injection
You may give other people a serious infection, or get a serious infection from them. The site you are about to visit is maintained by a third party who is solely responsible for its contents.
Call your healthcare provider right away if you have nausea, vomiting, or diarrhea that will not go away, or if you cannot take liquids by mouth. Signs and symptoms of low blood sugar may include headache, drowsiness, weakness, dizziness, confusion, irritability, hunger, fast heartbeat, sweating, and feeling jittery.
Go to Exdnatide Site. Before taking BYETTA, tell your healthcare provider if you have had pancreatitis, insery in your gallbladder gallstonesa history of alcoholism, or high blood triglyceride levels.
Add BYETTA to insulin glargine as a complementary action to help improve glycemic control
Oral medications dependent on threshold concentrations for efficacy, such as contraceptives or antibiotics, should be taken at least 1 hour before BYETTA. Use with caution in patients with renal transplantation or when initiating or escalating the dose in patients with moderate renal failure.
Use with caution with medications that have a narrow therapeutic index or require rapid gastrointestinal absorption. The most common side effects lnsert BYETTA include nausea, vomiting, diarrhea, feeling jittery, dizziness, headache, acid stomach, constipation, and weakness. Not a substitute for insulin and should not be used in patients with exenatde 1 diabetes or diabetic ketoacidosis.
BYETTA should not be used in people with type 1 diabetes or people with diabetic ketoacidosis a condition caused by very high blood sugar. Your risk for getting low blood sugar hypoglycemia is higher if you take BYETTA with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin. If pancreatitis is suspected, BYETTA should be discontinued promptly and should not be restarted if pancreatitis is confirmed. It is unknown whether patients with a history of pancreatitis are at increased risk for pancreatitis while using BYETTA; consider other antidiabetic therapies for these patients.
To report drug exposure during pregnancy call BYETTA has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, based on postmarketing data. BYETTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Should not be used in patients with severe renal impairment or end-stage renal disease.
Official BYETTA® (exenatide) injection Healthcare Professional Website
The most frequently reported adverse reactions leading to withdrawal for Byetta-treated patients were nausea 5. You exenatidd encouraged to report negative side effects of prescription drugs to the FDA. You may report side effects related to AstraZeneca products by clicking here. Based on postmarketing data BYETTA has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis.
No placebo-treated patients withdrew due to nausea or vomiting. BYETTA slows gastric emptying and can reduce the extent and rate of absorption of orally administered drugs. This product information is intended for US Healthcare Professionals only. Talk to your healthcare provider first if you are breastfeeding or plan to breastfeed.
All other trademarks are property of their respective owners. All other trademarks are property of their respective owners. AstraZeneca provides this link as a service to website visitors.
These may be symptoms of pancreatitis.
Tell your healthcare provider if you are pregnant or plan to become pregnant. Glucagon-like peptide-1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.